Registry of Senior Australians, Health Ageing Research Consortium, South Australian Health and Medical Research Institute, Adelaide, SA, 5000, Australia.
Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, VIC, 3052, Australia.
Aging Clin Exp Res. 2021 Jan;33(1):95-104. doi: 10.1007/s40520-020-01518-y. Epub 2020 Mar 11.
There is a high burden of antipsychotic use in residential aged care facilities (RACFs) and there is concern regarding potential inappropriate prescribing of antipsychotics in response to mild behavioural symptoms. Antipsychotic use has been associated with a higher risk of mortality in community-dwelling older adults with dementia, but few studies have examined associations upon RACF entry.
To examine associations between incident antipsychotic use and risk of mortality for people with and without diagnosed dementia in RACFs.
A retrospective cohort study, employing a new-user design (individuals did not receive an antipsychotic 6 months before enrolment) of 265,820 people who accessed RACFs in Australia between 1/4/2008 and 30/6/2015 was conducted. Cox regression models were used to examine adjusted associations between antipsychotic use in the first 100 days of RACF entry and mortality.
In the 100 days after entering care, 29,455 residents (11.1%) were dispensed an antipsychotic. 180,956 (68.1%) residents died [38,249 (14.4%) were related to cerebrovascular causes] over a median 2.1 years (interquartile range 1.0-3.6) follow-up. Of the residents included, 119,665 (45.0%) had a diagnosis of dementia. Incident antipsychotic use was associated with higher risk of mortality in residents with dementia (adjusted hazard ratio 1.20, 95% confidence interval 1.18-1.22) and without dementia (1.28, 1.24-1.31).
Initiation of antipsychotics after moving to RACFs is associated with a higher risk of mortality. Careful consideration of the potential benefits and harms should be given when starting a new prescription for antipsychotics for people moving to RACFs.
在养老院中使用抗精神病药物的负担很重,人们担心可能会因为轻度行为症状而不适当地开具抗精神病药物。抗精神病药物的使用与社区居住的老年痴呆症患者的死亡率升高有关,但很少有研究检查进入养老院时的关联。
研究在养老院中诊断为痴呆症和未诊断为痴呆症的人群中,使用抗精神病药物与死亡率之间的关联。
进行了一项回顾性队列研究,采用新用户设计(个体在入组前 6 个月未接受抗精神病药物治疗),纳入了 2008 年 4 月 1 日至 2015 年 6 月 30 日期间在澳大利亚入住养老院的 265820 人。使用 Cox 回归模型研究了在入住养老院后的 100 天内使用抗精神病药物与死亡率之间的调整关联。
在入住养老院后的 100 天内,有 29455 名居民(11.1%)开出了抗精神病药物。在中位数为 2.1 年(四分位距 1.0-3.6)的随访中,有 180956 名居民(68.1%)死亡[38249 名(14.4%)与脑血管疾病有关]。在所包括的居民中,有 119665 名(45.0%)有痴呆症的诊断。在有痴呆症和无痴呆症的居民中,新发抗精神病药物使用与死亡率升高相关(调整后的危险比分别为 1.20[95%置信区间 1.18-1.22]和 1.28[1.24-1.31])。
入住养老院后开始使用抗精神病药物与死亡率升高有关。在为入住养老院的人开始新的抗精神病药物处方时,应仔细考虑潜在的益处和危害。